Delving into the Latest Updates on Matrine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesUrogenital DiseasesDigestive System Disorders+ [1]

Active Indication

Candidiasis, VulvovaginalPelvic Inflammatory DiseaseUterine Cervicitis+ [4]

Inactive Indication-

Originator Organization

Chengdu First Pharmaceutical Co. Ltd.

Active Organization

Korea University of College of Medicine

Chengdu First Pharmaceutical Co. Ltd.

Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital)

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1985),

Candidiasis, VulvovaginalPelvic Inflammatory DiseaseUterine Cervicitis+ [1]

Regulation-

Login to view timeline

Structure

Molecular FormulaC15H24N2O

InChIKeyZSBXGIUJOOQZMP-JLNYLFASSA-N

CAS Registry519-02-8

Spinal cord injury is an intractable traumatic injury. The most common hurdles faced during spinal cord injury are failure of axonal regrowth and reconnection to target sites. These also tend to be the most challenging issues in spinal cord injury. As spinal cord injury progresses to the chronic phase, lost motor and sensory functions are not recovered. Several reasons may be attributed to the failure of recovery from chronic spinal cord injury. These include factors that inhibit axonal growth such as activated astrocytes, chondroitin sulfate proteoglycan, myelin-associated proteins, inflammatory microglia, and fibroblasts that accumulate at lesion sites. Skeletal muscle atrophy due to denervation is another chronic and detrimental spinal cord injury–specific condition. Although several intervention strategies based on multiple outlooks have been attempted for treating spinal cord injury, few approaches have been successful. To treat chronic spinal cord injury, neural cells or tissue substitutes may need to be supplied in the cavity area to enable possible axonal growth. Additionally, stimulating axonal growth activity by extrinsic factors is extremely important and essential for maintaining the remaining host neurons and transplanted neurons. This review focuses on pharmacotherapeutic approaches using small compounds and proteins to enable axonal growth in chronic spinal cord injury. This review presents some of these candidates that have shown promising outcomes in basic research (in vivo animal studies) and clinical trials: AA-NgR(310)ecto-Fc (AXER-204), fasudil, phosphatase and tensin homolog protein antagonist peptide 4, chondroitinase ABC, intracellular sigma peptide, (-)-epigallocatechin gallate, matrine, acteoside, pyrvate kinase M2, diosgenin, granulocyte-colony stimulating factor, and fampridine-sustained release. Although the current situation suggests that drug-based therapies to recover function in chronic spinal cord injury are limited, potential candidates have been identified through basic research, and these candidates may be subjects of clinical studies in the future. Moreover, cocktail therapy comprising drugs with varied underlying mechanisms may be effective in treating the refractory status of chronic spinal cord injury.

01 Jan 2025·MICROBIAL PATHOGENESIS

Combining with matrine restores ciprofloxacin efficacy against qnrS producing E. coli in vitro and in vivo

Article

Author: Ma, Danyang ; Zhu, Xiaolin ; Hu, Longfei ; Zhao, Qingyu ; Liu, Xudong ; Hao, Zhihui ; Zhu, Kui ; Wang, Peng

The exposure risk of plasmid-mediated quinolone resistance (PMQR) genes increases the incidence of resistant bacterial infections, has resulted in clinical treatment failures with ciprofloxacin, necessitating urgent implementation of novel strategies for controlling this situation. Matrine serves as the principal constituent of the traditional Chinese herb Sophora flavescens Ait. and exhibits pharmacological activities including anti-inflammatory, antibacterial, anti-tumor, and hepatoprotective effects. However, the precise mechanism by which matrine exhibits antibacterial activity remains incompletely elucidated. This study investigated the antibacterial potential and synergistic mechanism of matrine in combination with ciprofloxacin against qnrS-carrying E. coli. The clinical ciprofloxacin-resistant E. coli carrying the qnrS and the recombinant E. coli DE3 (pET28a-qnrS) were evaluated for their antibacterial activity in vitro, it was found that the combination of matrine/ciprofloxacin exhibited a significant synergistic, reducing the MIC value of ciprofloxacin against qnrS-positive E. coli by 4-fold, and it effectively reduced the bacterial load to undetectable levels within 10 h without obvious cytotoxicity. Moreover, consistent findings were observed in significantly reducing bacterial load within the mouse infection model. Molecular docking revealed that matrine was localized in the large loop B of the qnrS crystal structure, establishing hydrogen bonds with Thr-102 and Arg-101, thereby disrupting the activity of qnrS. Interaction analysis further confirmed that matrine could significantly inhibit the protective effect of qnrS on gyrase and restore the activity of ciprofloxacin against qnrS-positive E. coli. Matrine may serve as a qnrS inhibitor to restore the efficacy of ciprofloxacin, suggesting its potential as a novel antibiotic adjuvant for controlling bacterial infections.

01 Jan 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Potential application of matrine microneedles for the treatment of atopic dermatitis in joint skin

Article

Author: Ma, Yuxia ; Ma, Yuning ; Liu, Ziqi ; Wei, Xiaocen ; Shi, Yuwei ; Xing, Mengzhen ; Ma, Fengjun ; Wang, Peijie ; Liu, Wei

Atopic dermatitis (AD) commonly manifests in skin areas subjected to flexion, particularly joints. This underscores the importance of dissolving microneedles (DMNs) used in AD treatment having strong skin adhesion to prevent drug delivery interruption due to patch detachment during patient activity. Moreover, matrine (MAT), a prominent active ingredient derived from the natural plant Sophora flavescens, is known for its significant efficacy in treating skin inflammation, itching, and allergic diseases. Herein, we presented MAT-loaded DMNs (MAT-DMNs) specifically tailored for joint skin application in AD treatment. MAT-DMNs can rapidly dissolve and hydrate after application, demonstrating adhesive properties on ex vivo pig skin, rat abdominal skin, and finger joint skin, thereby ensuring sustained and uninterrupted drug delivery to the skin. In vitro evaluations revealed that MAT-DMNs exhibited 24-hour first-order release profiles with cumulative penetration rates of 78.70 ± 4.24 % and 77.14 ± 6.65 % for the low-dose and high-dose groups, respectively. Furthermore, these DMNs showed excellent skin compatibility and therapeutic efficacy in AD mice models. Specifically, the skin lesion score in MAT-DMNs group was significantly lower (2.67 ± 0.40) compared to the model group (11.60 ± 1.62) and the blank DMNs group (10.80 ± 1.67). MAT-DMNs effectively alleviated AD symptoms such as itching and inflammation by reducing epidermal thickening, decreasing mast cell infiltration, and lowering the expression of Th2 cytokines (IL-4 and IL-10) and pro-inflammatory factors (IL-1β, IL-6, and TNF-α) compared to the blank DMNs group (p < 0.01). These findings suggest that MAT-DMNs hold promise for clinical AD treatment, particularly for skin diseases commonly affecting joint areas.

1

News (Medical) associated with Matrine

05 Sep 2022

·www.globenewswire.com

Orion recalls Devisol Salmiakki dietary supplement from consumers

ORION CORPORATION PRESS RELEASE 5 SEPTEMBER 2022 AT 8.00 EEST Orion recalls Devisol Salmiakki dietary supplement from consumers Orion is recalling all Devisol Salmiakki dietary supplement packages from consumers due to excessive levels of matrine in the product. Devisol Salmiakki has been on sale in Finland only starting from December 2021. Consumers are requested to return both opened and unopened Devisol Salmiakki products to the nearest pharmacy at the latest on 13 October 2022. The products will be reimbursed for the consumers. Empty packages or free samples will not be reimbursed. The recall does not concern Orion’s other Devisol products. The recall is due to levels of matrine in the licorice extract used in the Devisol Salmiakki product which have been found to exceed the maximum level allowed by the EU. Matrine occurs naturally in certain plants and is also used as a pesticide. Regarding matrine, there is no EU-level risk assessment and approval, and there is therefore no certainty about the safety of foodstuffs containing it. As a precaution, all batches of Devisol Salmiakki on the market are withdrawn. The daily recommended dose of Devisol Salmiakki is one tablet, in which case the exposure to matrine through this preparation is assumed to be low. Orion has not received any reports of adverse effects related to the Devisol Salmiakki product, and Orion is not aware of any consumer reports related to the safety of the Devisol Salmiakki product. The recall has no material financial impact on Orion. Orion apologises for the inconvenience that returning the product causes for our customers. Further information: Product information and customer service: tel. +358 10 439 8250Media contact: Terhi Ormio, Vice President, Communications, tel. +358 50 966 4646 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orion.fi Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.www.orion.fi/ Attachments Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl

100 Deals associated with Matrine

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Candidiasis, Vulvovaginal	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Pelvic Inflammatory Disease	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Uterine Cervicitis	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985
Vaginitis	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enteritis	Preclinical	CN	Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital)	14 Feb 2017
stress oxidative	Preclinical	CN	Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital)	14 Feb 2017
Colitis	Preclinical	KR	Korea University of College of Medicine	19 Jan 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2016	Not Applicable	-	-	Matrine	dwmcavjoyl(zzvmnlrmdp) = ljauqccesh bvtrocjevl (rbfoxveqtx ) View more	-	15 Nov 2016
				Levofloxacin	dwmcavjoyl(zzvmnlrmdp) = wiparymqdc bvtrocjevl (rbfoxveqtx ) View more